MX2016005174A - Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor. - Google Patents

Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.

Info

Publication number
MX2016005174A
MX2016005174A MX2016005174A MX2016005174A MX2016005174A MX 2016005174 A MX2016005174 A MX 2016005174A MX 2016005174 A MX2016005174 A MX 2016005174A MX 2016005174 A MX2016005174 A MX 2016005174A MX 2016005174 A MX2016005174 A MX 2016005174A
Authority
MX
Mexico
Prior art keywords
adenosine
methyl
pain
prevention
compounds
Prior art date
Application number
MX2016005174A
Other languages
English (en)
Other versions
MX367707B (es
Inventor
Fang Jim-Min
Lian LIN Yun-
Hsin LIN Jung-
Jung LIN Chun-
Chern Yijuang
Kuei HUANG Nai-
Li WANG Hung-
Pang-hsien TU Benjamin
Cheng Chen Chih-
Original Assignee
Academia Sinica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Academia Sinica filed Critical Academia Sinica
Publication of MX2016005174A publication Critical patent/MX2016005174A/es
Publication of MX367707B publication Critical patent/MX367707B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se revelan compuestos para el uso en la prevención y el tratamiento de una enfermedad neurodegenerativa y el dolor. En una realización de la invención, el compuesto se selecciona del grupo que consiste en N6-[(3-halotien-2-il)metil]adenosina, N6-[(4-halotien-2-il)metil]adenosina y N6-[(5-halotien-2-il)metil] adenosina. En otra realización de la invención, el compuesto se selecciona del grupo que consiste en N6-[(2-bromotien-3-il)metil]a denosina, N6-[(4-bromotien-3-il)metil]adenosina, N6-[(5-bromotien-3-il)metil]adenosina, N6-[(2-clorotien-2-il)metil ]adenosina, N6-[(4-clorotien-3-il)metil]adenosina y N6-[(clorotien-3-il)meti]adenosina. También se revelan métodos para fabricar y usar los mismos.
MX2016005174A 2013-10-23 2014-10-22 Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor. MX367707B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361894699P 2013-10-23 2013-10-23
PCT/US2014/061734 WO2015061426A1 (en) 2013-10-23 2014-10-22 Compounds for use in prevention and treatment of neurodegenerative diseases and pain

Publications (2)

Publication Number Publication Date
MX2016005174A true MX2016005174A (es) 2016-08-11
MX367707B MX367707B (es) 2019-09-03

Family

ID=52993493

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005174A MX367707B (es) 2013-10-23 2014-10-22 Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.

Country Status (14)

Country Link
US (1) US10301348B2 (es)
EP (1) EP3060566B1 (es)
JP (1) JP6534997B2 (es)
KR (1) KR102313314B1 (es)
CN (1) CN106414456B (es)
AU (1) AU2014340114B2 (es)
BR (1) BR112016008901B1 (es)
CA (1) CA2927699C (es)
IL (1) IL245103B (es)
MX (1) MX367707B (es)
RU (1) RU2695358C2 (es)
SG (1) SG11201603063WA (es)
WO (1) WO2015061426A1 (es)
ZA (1) ZA201603118B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107614686A (zh) 2015-05-29 2018-01-19 小利兰·斯坦福大学托管委员会 用于降低含有延伸的核苷酸重复序列的基因的有害活性的核苷试剂
CN110799517A (zh) * 2017-01-27 2020-02-14 中央研究院 用于预防及治疗疼痛的具有止痛效果的化合物
TW202400186A (zh) * 2022-02-10 2024-01-01 中央研究院 治療脊髓損傷之方法及用於其中之組成物
WO2024010910A1 (en) * 2022-07-07 2024-01-11 Academia Sinica Method of treating schizophrenia and composition for use therein

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003148A2 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Heteroaromatic derivatives of adenoside
US5034381A (en) * 1988-01-07 1991-07-23 Ciba-Geigy Corporation 2-(substituted amino) adenosines as antihypertensives
ATE147074T1 (de) * 1990-09-25 1997-01-15 Rhone Poulenc Rorer Int Verbindungen welche antihypertensive und antiischemische eigenschaften besitzen
US5561134A (en) * 1990-09-25 1996-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Compounds having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties
UY27939A1 (es) * 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
US20120295863A1 (en) 2009-11-13 2012-11-22 Yun-Lian Lin Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases
CN102812033B (zh) 2009-12-10 2015-11-25 中国医学科学院药物研究所 N6-取代腺苷衍生物和n6-取代腺嘌呤衍生物及其用途
US9311831B2 (en) 2012-02-09 2016-04-12 Brand Bumps, LLC Decorative detectable warning panel having improved grip
CN104363757B (zh) * 2012-02-11 2017-05-24 中央研究院 治疗疼痛的方法及组合物

Also Published As

Publication number Publication date
NZ719740A (en) 2021-02-26
MX367707B (es) 2019-09-03
BR112016008901A2 (pt) 2020-05-12
CA2927699C (en) 2022-07-05
IL245103A0 (en) 2016-06-30
JP6534997B2 (ja) 2019-06-26
RU2016118282A (ru) 2017-11-28
EP3060566A1 (en) 2016-08-31
ZA201603118B (en) 2019-04-24
CN106414456A (zh) 2017-02-15
AU2014340114A1 (en) 2016-05-26
SG11201603063WA (en) 2016-05-30
WO2015061426A1 (en) 2015-04-30
RU2695358C2 (ru) 2019-07-23
US10301348B2 (en) 2019-05-28
KR102313314B1 (ko) 2021-10-19
EP3060566A4 (en) 2017-06-14
US20160264613A1 (en) 2016-09-15
KR20160086852A (ko) 2016-07-20
EP3060566B1 (en) 2018-09-05
IL245103B (en) 2019-02-28
CN106414456B (zh) 2018-12-14
CA2927699A1 (en) 2015-04-30
AU2014340114B2 (en) 2018-10-18
BR112016008901B1 (pt) 2022-08-23
JP2016535019A (ja) 2016-11-10
RU2016118282A3 (es) 2018-06-18

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
IL264049A (en) Compounds, preparations and methods for treating the disease
IL264156A (en) Compounds, preparations and methods for treating the disease
PH12016501107A1 (en) Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
PH12015502788A1 (en) Antibody formulations and methods
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
HK1220324A1 (zh) 用於治療血管緊張素相關疾病的方法、化合物和組合物
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
HK1222331A1 (zh) 修飾的繆勒抑制物質 蛋白及其用於疾病治療的用途
EP3046582A4 (en) Uses of modified mullerian inhibiting substance (mis) proteins for the treatment of neurodegenerative diseases
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,.
MX2016005174A (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.
EP3730144A4 (en) AGENTS FOR TREATMENT OF DISEASES OF THE NERVOUS SYSTEM
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
MX2016002931A (es) Moduladores del receptor x hepatico (lxr).
EP2994156A4 (en) Compounds, compositions and methods for the treatment of diseases through inhibiting tgf- activity

Legal Events

Date Code Title Description
FG Grant or registration